Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA's Marks: Gene Therapy Success Could Hinge On Regulatory Convergence

Executive Summary

Biologics center's director encourages sponsors to invite other regulators to early FDA meetings in effort to scale up markets.

You may also be interested in...



Gene Therapy Manufacturing Hitch Solved, Bluebird Aims For European Debut In 2020

The EMA has declared itself satisfied with ‘refined manufacturing specifications’ for the beta thalassemia treatment

CBER Implements Pre-Clinical Meeting Program For Biologics, Gene Therapy Sponsors

INTERACT program will allow sponsors to ask FDA questions about manufacturing and other technical issues to help streamline development.

US FDA Could Use More Foreign Investigators If It Could Find Them, Woodcock Says

Hiring travails, inspection pre-announcement, lack of translators highlighted in congressional hearing on FDA foreign inspections.

Topics

Related Companies

UsernamePublicRestriction

Register

PS141234

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel